Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
Title:
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
Author:
Hodi, F Stephen Chesney, Jason Pavlick, Anna C Robert, Caroline Grossmann, Kenneth F McDermott, David F Linette, Gerald P Meyer, Nicolas Giguere, Jeffrey K Agarwala, Sanjiv S Shaheen, Montaser Ernstoff, Marc S Minor, David R Salama, April K Taylor, Matthew H Ott, Patrick A Horak, Christine Gagnier, Paul Jiang, Joel Wolchok, Jedd D Postow, Michael A